8-K ·Filed Mar 31, 2026
earnings-rerun-backfill
Actionable Insight ◆ Mixed
Monitor H2 2026 for HCC trial readout and Q2 2026 for TTI-109 healthy volunteer data, which are key catalysts. The EPS miss and trial delay are near-term headwinds, but improved IPF data may support longer-term value if replicated.
Final — all horizons settled through T+60d ⚠ clustered
TVRD ▼ -36.33% at T+60d
NEUTRAL call -36.33% · α vs SPY -49.71% · entry $3.00 → $1.91
T+1d
+0.67%
call +0.67% · α +0.59%
$3.02
settled 7mo ago
T+5d
-1.33%
call -1.33% · α -5.10%
$2.96
settled 7mo ago
T+20d
+2.00%
call +2.00% · α -7.72%
$3.06
settled 6mo ago
T+60d
-36.33%
call -36.33% · α -49.71%
$1.91
settled 4mo ago
Price Chart
Loading chart...
Executive Summary
Tvardi Therapeutics reported Q4 2025 net loss per share of $0.78, missing consensus of $0.72, on reduced R&D spending. Positive IPF trial data trends were highlighted, but HCC trial readout delayed to H2 2026. Cash runway extends into Q4 2026.
Key Financial Metrics
EPS
−$0.78
est −$0.72 · -8.3%
Revenue
$0.00
est $0.00 · 0.0%
Rating
miss
Key Facts
- Q4 2025 net loss per share was $0.78, missing consensus of $0.72 by 8.9%
- R&D expenses decreased to $5.5M from $8.6M YoY due to lower TTI-101 costs, partially offset by TTI-109 development
- Additional IPF trial analysis showed a 9.4% reduction in fibrosis score vs 2.4% for placebo and a 4.5-fold greater decline in IL-6
- Topline data from the HCC Phase 2 trial of TTI-101 delayed to H2 2026 to allow for data maturation
- Healthy volunteer study of TTI-109 on track for Q2 2026 readout
- Cash, cash equivalents, and short-term investments totaled $30.8M as of Dec 31, 2025, sufficient to fund operations into Q4 2026
Financial Impact
Net loss of $7.3M for Q4 2025, EPS miss of $0.06 vs consensus
epsr&d expensescash runway
Risk Factors
- Clinical trial delays increase development risk and extend path to potential commercialization
- EPS miss may pressure stock price despite positive trial signals
- Limited cash runway (into Q4 2026) may necessitate future financing, potentially dilutive
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-037724 |
| Document: tm2610603d1_8k.htm | 0001104659-26-037724 |
| Document: 0001104659-26-037724-index-headers.html | 0001104659-26-037724 |
| Document: 0001104659-26-037724-index.html | 0001104659-26-037724 |
| Document: 0001104659-26-037724.txt | 0001104659-26-037724 |
| 8-K Data (Synthetic) | 0001104659-26-037724 |
10 reports for TVRD
60% Hit rate @ T+20 Went positive at some point 4 of 5 best @ T+1▲ +61.29%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 9w ago | Institutional Cluster | $1.86 $1.61 | ▲ +13.44% | ▲ +12.91% | $0.8650 (+53.49%) |
Aug 14, 2026 10w ago | 8-K | $1.90 $1.83 | ▼ −3.68% | ▼ −1.69% | $0.8650 (−54.47%) |
Aug 14, 2026 10w ago | Press Release | $1.90 $1.83 | ▼ −3.68% | ▼ −1.69% | $0.8650 (−54.47%) |
Jul 30, 2026 12w ago | 8-K | $2.10 $1.80 | ▼ −14.29% | ▼ −18.25% | $0.8650 (−58.81%) |
Jul 7, 2026 16w ago | 8-K | $3.10 $2.02 | ▼ −34.84% | ▼ −36.17% | $0.8650 (−72.10%) |
May 14, 2026 23w ago | EFFECT | $3.96 $2.64 | ▲ +33.33% | ▲ +32.48% | $0.8650 (+78.16%) |
May 13, 2026 23w ago | EFFECT | $3.95 $2.71 | ▲ +31.39% | ▲ +30.78% | $0.8650 (+78.10%) |
May 8, 2026 24w ago | Press Release | $4.18 $2.89 | ▼ −30.86% | ▼ −30.88% | $0.8650 (−79.31%) |
Apr 23, 2026 26w ago | DEFA14A | $3.10 $3.59 | ▲ +15.81% | ▲ +11.78% | $0.8650 (−72.10%) |
Mar 31, 2026 30w ago | 8-K | $3.00 $3.06 | ▲ +2.00% | ▼ −7.72% | $0.8650 (−71.17%) |
Showing 10 of 10
US Market Status
Market Closed — Opens Thu (11h 27m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers